TITLE

Letter: Pyrimethamine toxicity

AUTHOR(S)
Briggs, M
PUB. DATE
January 1974
SOURCE
British Medical Journal;1/5/1974, Vol. 1 Issue 5896, p40
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
64109320

 

Related Articles

  • Pyrimethamine overdose.  // Reactions Weekly;12/17/2011, Issue 1382, p29 

    The article describes the case of a neonate who developed various toxicities after administration of pyrimethamine overdoses for asymptomatic congenital toxoplasmosis.

  • Pulmonary toxicity of malaria prophylaxis. Davidson, A.C.; Bateman, C.; Shovlin, C.; Marrinan, M.; Burton, G.H.; Cameron, I.R. // BMJ: British Medical Journal (International Edition);11/12/88, Vol. 297 Issue 6658, p1240 

    Examines the pulmonary toxicity of malaria prophylaxis. Impact of toxicity on other body organs; Occurrence of systemic illness after pyrimethamine-sulfadoxine treatment; Importance of lung biopsy for the determination of eosinophilic pneumonia.

  • Letters. Elden, Susan; Jagoe, George; Misiorowska, Aleksandra // Africa Health;Jul2013, Vol. 35 Issue 5, p15 

    Several letters to the editor are presented on topics including polio eradication in Africa and use of suiphadoxine and pyrimethamine in preventing malaria in children under 5.

  • Pneumocystis carinii Pneumonia Treated with Pyrimethamine and Sulfadiazine. Kirby, Henry B.; Kenamore, Bruce; Guckian, James C. // Annals of Internal Medicine;Oct71, Vol. 75 Issue 4, p505 

    Provides information on a study on the results of pyrimethamine and sulfadiazine therapy in adults with Pneumocystis carinii. Evaluation of the toxicity of the drugs; Patients of different ethnic backgrounds admitted for Pneumocystis carinii pneumonia; Information on antimicrobial agents.

  • Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria. Ringwald, P. // BMJ: British Medical Journal (International Edition);5/22/2004, Vol. 328 Issue 7450, p1259 

    Presents a letter to the editor of the May 22, 2004 issue of the "British Medical Journal," regarding the use of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria. Assessment of the efficacy of antimalarial drugs by the World Health Organization; Evidence of the resistance to the...

  • Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria. White, Nicholas // BMJ: British Medical Journal (International Edition);5/22/2004, Vol. 328 Issue 7450, p1259 

    Presents a letter to the editor of the May 22, 2004 issue of the "British Medical Journal," regarding the use of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria. Resistance of malaria in Malawi to the combination drug.

  • Defending the Use of Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment for Malaria in Pregnancy: A Short-Sighted Strategy. Harrington, Whitney E.; Fried, Michal; Duffy, Patrick E.; Gutman, Julie; Taylor, Steve; Meshnick, Steven R.; ter Kuile, Feiko O. // Journal of Infectious Diseases;2/1/2016, Vol. 213 Issue 3, p496 

    A letter to the editor is presented in response to the article related to an observational study of sulfadoxine-pyrimethamine for intermittent preventive treatment for malaria in pregnancy (SP-IPTp) in Malawi, Africa by J Gutman and colleague.

  • Single-Dose Sulfadoxine-Pyrimethamine in Intermittent Preventive Treatment of Malaria. Gosling, Roly D.; Schellenberg, David M.; Chandramohan, Danial // Journal of Infectious Diseases;6/1/2006, Vol. 193 Issue 11, p1609 

    A letter to the editor is presented in response to the article titled "Parasitological Rebound effect and Emergence of Pyrimethanine Resistance in Plasmodium Falciparum After Single-Dose Sulfadoxine-Pyrimethamine," published in a 2006 issue of the "Journal of Infectious Diseases."

  • The potential role of azithromycin in the treatment or prophylaxis of toxoplasmosis. Chang, H. R. // International Journal of STD & AIDS;Jan1996 Supplement 1, Vol. 7, p18 

    Infection with Toxoplasma gondii is the most common parasitic infection worldwide with an estimated prevalence of 1-2 billion people. The risk of developing severe toxoplasmosis is higher for immunocompromised individuals and fetuses of mothers who have acquired a primo-infection. The current...

  • Cardiovascular Toxicity of Valdecoxib. Ray, Wayne A.; Griffin, Marie R.; Stein, C. Michael // New England Journal of Medicine;12/23/2004, Vol. 351 Issue 26, p2767 

    A letter to the editor is presented discussing the cardiovascular toxicity of valdecoxib.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics